Literature DB >> 28912249

Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis.

Jing-Hong Hu1, Jui-Hsiang Tang2, Cheng-Hui Lin3,4, Yin-Yi Chu3,4, Nai-Jen Liu3,4.   

Abstract

This meta-analysis was performed to determine the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) in assessing primary cholangiocarcinoma (CCA) and CCA with lymph node and distant metastasis. A literature search for studies reporting the use of 18F-FDG-PET for preoperative work-up/staging in patients with CCA was performed. Diagnostic OR (DOR) was used as an index of diagnostic performance of FDG-PET/CT in predicting primary CCA, lymph node metastases, and distant metastases. The pooled DOR was 9.34 (95% CI 4.27 to 20.42) and the area under the summary receiver operating characteristic (SROC) curve was 0.8643 (SE=0.0362), indicating overall good discriminatory test performance in predicting primary CCA. Subgroup analyses based on the primary tumor site showed better diagnostic performance for intrahepatic CCA (DOR=54.44, 95% CI 13.44 to 220.49), both intrahepatic and extrahepatic CCA (DOR=32.96, 95% CI 1.41 to 768.80) and gallbladder cancer (DOR=12.93, 95% CI 1.97 to 84.80), than for extrahepatic CCA (DOR=2.55, 95% CI 0.71 to 9.20) and hilar CCA (DOR=2.75, 95% CI 0.17 to 43.72). The pooled DOR for the prediction of lymph nodes metastases in 10 studies was 11.34 (95% CI 4.79 to 26.80), with moderate heterogeneity (Cochran Q=15.14, p=0.0872, I2=40.5%). The area under the SROC curve was 0.8584 (SE=0.0729). In conclusion, 18F-FDG-PET and PET/CT were found to be accurate in the evaluation of primary tumors, lymph node metastasis, and distant metastasis in patients with CCA. © American Federation for Medical Research (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  18F-FDG-PET; cholangiocarcinoma; lymph node metastasis; meta-analysis

Mesh:

Substances:

Year:  2017        PMID: 28912249     DOI: 10.1136/jim-2017-000472

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  10 in total

1.  Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for "Borderline Resectable" in the Field of Surgery for Hilar Cholangiocarcinoma.

Authors:  Ryusei Matsuyama; Daisuke Morioka; Ryutaro Mori; Yasuhiro Yabushita; Seigo Hiratani; Yohei Ota; Takafumi Kumamoto; Itaru Endo
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

2.  18F-fluorodeoxyglucose positron emission tomography for intrahepatic cholangiocarcinoma N- and M-staging: should guidelines recommend it at last?

Authors:  Maurizio Zizzo; Magda Zanelli; Francesca Sanguedolce; Annibale Versari; Pierpaolo Pattacini; Andrea Morini; Federica Mereu; Antonia Lavinia Zuliani; Alessandro Giunta
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

3.  The Role of 18F-FDG PET/CT in staging of gallbladder carcinomas.

Authors:  Esra Arslan; Tamer Aksoy; Nevra Dursun; Rıza Umar Gürsu; Mert Mahsuni Sevinç; Tevfik Fikret Çermik
Journal:  Turk J Gastroenterol       Date:  2020-02       Impact factor: 1.852

4.  Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma: A STROBE study.

Authors:  Jae Pil Hwang; Jong Ho Moon; Hee Kyung Kim; Min Hee Lee; Chae Hong Lim; Soo Bin Park; Joon-Kee Yoon; Jung Mi Park
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

5.  Impact of 18F-FDG PET/MR based tumor delineation in radiotherapy planning for cholangiocarcinoma.

Authors:  Gauthier Delaby; Bahar Ataeinia; Jennifer Wo; Onofrio Antonio Catalano; Pedram Heidari
Journal:  Abdom Radiol (NY)       Date:  2021-03-27

6.  Genetic features associated with 18F-FDG uptake in intrahepatic cholangiocarcinoma.

Authors:  Keun Soo Ahn; Koo Jeong Kang; Yong Hoon Kim; Tae-Seok Kim; Bong-Il Song; Hae Won Kim; Daniel O'Brien; Lewis R Roberts; Jeong Woo Lee; Kyoung Sook Won
Journal:  Ann Surg Treat Res       Date:  2019-03-28       Impact factor: 1.859

Review 7.  Radiologic Evaluation and Structured Reporting Form for Extrahepatic Bile Duct Cancer: 2019 Consensus Recommendations from the Korean Society of Abdominal Radiology.

Authors:  Dong Ho Lee; Bohyun Kim; Eun Sun Lee; Hyoung Jung Kim; Ji Hye Min; Jeong Min Lee; Moon Hyung Choi; Nieun Seo; Sang Hyun Choi; Seong Hyun Kim; Seung Soo Lee; Yang Shin Park; Yong Eun Chung
Journal:  Korean J Radiol       Date:  2020-08-28       Impact factor: 3.500

8.  Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [18F]F-FDG PET/CT in Patients with Liver Malignancies.

Authors:  Dheeratama Siripongsatian; Chetsadaporn Promteangtrong; Anchisa Kunawudhi; Peerapon Kiatkittikul; Natphimol Boonkawin; Chatchawarin Chinnanthachai; Attapon Jantarato; Chanisa Chotipanich
Journal:  Mol Imaging Biol       Date:  2022-04-29       Impact factor: 3.484

9.  Intrahepatic cholangiocarcinoma with gastric metastasis misdiagnosed as primary gastric cancer: A case report and literature review.

Authors:  Qingshun Zhu; Shengyong Zhai; Enkang Ge; Lei Li; Xuguang Jiao; Jinqiu Xiong; Guangxu Zhu; Yuanyuan Xu; Jianjun Qu; Zhengjiang Wang
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

10.  Nerve Fibers in the Tumor Microenvironment as a Novel Biomarker for Oncological Outcome in Patients Undergoing Surgery for Perihilar Cholangiocarcinoma.

Authors:  Jan Bednarsch; Jakob Kather; Xiuxiang Tan; Shivan Sivakumar; Claudio Cacchi; Georg Wiltberger; Zoltan Czigany; Florian Ulmer; Ulf Peter Neumann; Lara Rosaline Heij
Journal:  Liver Cancer       Date:  2021-05-06       Impact factor: 11.740

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.